drugset / Trial / NCT06079775
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
Phase 1
Completed
53 enrolled
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority · collabShionogi · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
A Phase 1, Open-Label, Drug-drug Interaction, and Randomized, Double-blind, Controlled, Multiple-dose Pharmacokinetics and Safety Study of Xeruborbactam Oral Prodrug (QPX7831) in Combination with Ceftibuten in Healthy Adult Participants
Timeline
- Start
- 2024-01-30
- Primary completion
- 2025-01-05
- Completion
- 2025-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceftibuten | Small molecule | — | Oral |
| Subject | Xeruborbactam | Small molecule | — | Oral |